A treatment and/or preventive agent for prostatic hypertrophy includes a compound having an antagonistic effect to an angiotensin II receptor, or a pharmaceutically acceptable salt or a prodrug thereof, as an active ingredient, wherein said compound having an antagonistic effect to an angiotensin II receptor is one or more compounds selected from the group consisting of losartan, potassium losartan, candesartan, candesartan cilexetil, balsartan, eprosartan, zolasartan, telmisartan, irbesartan, tasosartan, olmesartan medoxomil, and olmesartan.